Head-to-head · free
AbbVie vs Thermo Fisher Scientific
ABBV vs TMO — return on capital, cash generation, margins and balance sheet side by side.
ABBV
7 / 9
measures where ABBV leads
TMO
2 / 9
measures where TMO leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | ABBV · FY2025 | TMO · FY2025 |
|---|---|---|
| Revenue | $61.2B | $44.6B |
| Net income | $4.2B | $6.7B |
| Revenue growth (yearly, multi-year) | 2.1% | 3.2% |
| Free cash flow | $17.8B | $6.3B |
| Free cash flow margin | 29.1% | 14.1% |
| Net cash / (debt) | — | — |
| ROIC | 14.4% | 8.3% |
| Return on equity | — | 13.0% |
| Gross margin | 70.2% | 40.9% |
| Operating margin | 32.8% | 18.2% |
| Net debt / EBITDA | 2.68x | 2.81x |
Figures are as reported by each company; latest fiscal year shown.
Where AbbVie's cash went (FY2025)
- Capital spending
- $1.2B
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where Thermo Fisher Scientific's cash went (FY2025)
- Capital spending
- $1.5B
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free